Abstract
Platinum-based drugs are widely used as a master key in the multiple cancer therapies, while limited by the adverse side effects during the in vivo circulation. To settle the aforementioned problems, we prepare a series of polymer-platinum conjugates by utilizing the “stealth” polyethylene glycol and legumain-cleavable oligopeptide.We select MGC803 cells overexpressing the legumain and MKN28 cells negatively expressing the legumain as well as the normal stomach cells to compose the test groups.In vitro cytotoxicity studies indicate the polymer-platinum conjugates with the assistance of Ala-Ala-Asn tripeptide can effectively inhibit the growth of MGC-803 cells than control groups. Meanwhile, the MPEG polymer show better anticancer ability than 4-arm-PEG polymer. However, in the group of MKN28 cells, both polymer-platinum conjugates express weak cytotoxicity due to lacking of the mediation of legumain.Hence, the synthesized polymer-platinum conjugates exhibiting great potential in avoiding the side effects and enhancing the therapy ability will be valuable for the platinum-cancer therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
